J.P. Morgan Healthcare Conference January 13, 2026 Brian Van Wagener Chief Financial Officer Safe Harbor and Other Information This presentation and associated commentary contain forward-looking statements regarding Veeva's future plans and expected performance, market size and opportunity, and financial outlook, including guidance provided as of November 20, 2025, about Veeva's expected future financial results and long-term financial goals for 2030. These statements are based on our current expectation an ...

Key Objectives & Platform - Denali aims to transform lives by delivering biotherapeutics to the whole body, including the brain[11] - The company's TransportVehicle (TV) platform enables systemic delivery of biologics to the brain and other hard-to-target tissues[12, 24] - Denali's TransportVehicle has demonstrated best-in-class properties for brain delivery, modularity, and safety[50] Near-Term Commercial Opportunities - Denali anticipates launching tividenofusp alfa (DNL310) in 2026 and DNL126 in 2027, establishing a commercial foundation for the Enzyme TransportVehicle (ETV) franchise[13] - Tividenofusp alfa has a PDUFA target action date of April 5, 2026, for accelerated approval[61, 81] - The ETV franchise targets lysosomal storage disorders (LSDs), with a combined market opportunity exceeding $1 billion for MPS II and MPS IIIA[13, 107] Pipeline & Milestones - Denali has a broad clinical-stage pipeline, including programs for Alzheimer's disease, with several near-term milestones expected[14] - The company anticipates an approval decision for tividenofusp alfa, ETV:SGSH Phase 1/2 data, and initiation of Phase 1 studies for OTV:MAPT, ATV:Abeta, and ETV:GAA in the first half of 2026[16] - Denali is developing the next generation of enzyme replacement therapies designed to treat brain and body manifestations of serious genetic diseases[61, 64] Financial Position - Denali has a strong financial foundation with approximately $873 million in cash and investments as of Q3 2025, plus $488 million from royalty financing and an equity capital raise in December 2025[146]

BRIUMVI Market Position and Growth - BRIUMVI is the first and only anti-CD20 therapy for Relapsing forms of Multiple Sclerosis (RMS) delivered in a 1-hour infusion every 6 months after the starting dose[9, 21] - Anti-CD20s capture approximately 50% of the dynamic and overall Multiple Sclerosis (MS) market share, representing a ~$10 billion market in the U S today[12] - BRIUMVI has achieved significant uptake, with >97% of the top 200 MS centers using it and ~90% of high decile Healthcare Professionals (HCPs) prescribing it[16] - The company's goal is to become the 1 prescribed anti-CD20 in RMS based on dynamic market share[14] Financial Performance and Guidance - Cumulative BRIUMVI U S net revenue LTD is approximately $992 million[19] - BRIUMVI U S net revenue for Q4 2025 was approximately $182 million, and for FY 2025, it was approximately $594 million[19] - Total global revenue for FY 2025 was approximately $616 million, representing ~90% growth from FY 2024 to FY 2025 and ~20% growth from Q3 2025 to Q4 2025[19] - The company projects FY 2026 total global net revenue to be approximately $875-900 million, with U S net revenue of approximately $825-850 million[45] Pipeline Expansion and Future Launches - The company is developing a consolidated dosing schedule for IV BRIUMVI, with a target launch in 2027, pending top-line data from the ENHANCE pivotal study expected in mid-2026[27, 33] - A self-administered subcutaneous (SubQ) formulation of BRIUMVI is in development, with a target launch in 2028, pending top-line data expected by YE26/Q1 27[27, 38] - The SubQ formulation is expected to significantly increase the total addressable market by reaching a distinct patient segment, augmenting the current IV business[39, 41]

Financial Performance and Outlook - Ambarella expects total revenue growth in the 36% to 38% range for F2026, reaching approximately $390 million at the midpoint[40] - Q4 revenue guidance is $97 million to $103 million, with a midpoint of $100 million[40] - Non-GAAP gross margin for Q4 is estimated to be 59% to 60.5%[40] - The company has $295 million net cash with no debt and 16 consecutive years of positive free cash flow[14] - Edge AI 5-Year Revenue CAGR is 64%[15] Market and Technology - Ambarella has shipped cumulatively over 40 million Edge AI SoCs[5] and 400 million SoCs[5] - The Edge AI SAM is projected to grow from $5.5 billion in F2026 to $12.9 billion in F2031, representing an approximate 18% CAGR[31] - IoT applications are estimated to contribute approximately 70% of F2025 revenue[32], with the IoT SAM estimated at $2.5 billion in F2026 and $5.7 billion in F2031[34] - Auto applications are estimated to contribute approximately 30% of F2025 revenue[35], with the Auto SAM estimated at $3.0 billion in F2026 and $7.2 billion in F2031[37] Strategic Initiatives - Ambarella has invested $1.3 billion cumulatively in AI R&D over the last decade[5] - The company's technology portfolio includes 2nm in development, 5nm representing approximately 45% of revenue, and 10nm representing approximately 35% of revenue[14]

January 2026 Investor Presentation Forward-Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Securities Exchange Act of 1934 and the Securities Act of 1933. The forward-looking statements include statements concerning, among other things, our future business model and strategies, our financial model and structure, market and market share growth, industry trends, customer demand and growth opportunities. In some instances, you ...

J.P. Morgan 44th Annual Healthcare Conference failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelli ...

44th Annual J.P. Morgan Healthcare Conference Stefan Oelrich Member Of The Board Of Management Of Bayer AG President Pharmaceuticals January 13th, 2026 Our Strategy is Showing Tangible Results Nubeqa and Kerendia with sustained growth momentum, offsetting Xarelto declines Next wave of growth with Beyonttra, Lynkuet and Asundexian Robust Eylea Franchise and Foundational Business Driver for near-term growth Renew topline Grow pipeline value New Innovation Model yielding success Five new indications or product ...

January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the ability of the Company's portfolio to drive long-term shareholder value; ...

Financial Performance & Expectations - Danaher anticipates Q4 2025 results will be slightly ahead of expectations[7, 8] - The company expects Q4 core revenue growth to be toward the high end of their low-single digit percentage guidance[8] - FY 2025 adjusted EPS is expected to be toward the high-end of the guidance range of $7.70 to $7.80[9] - Initial 2026 expectations include core revenue growth of +3% to +6%, leading to high-single digit (HSD) adjusted earnings per share (EPS) growth and >100 bps adjusted operating profit margin expansion[10] - Danaher estimates 2025 total revenue to be approximately $24.5 billion[14] Business Segment Performance - Biotechnology represents 59.5% of 2025E total revenue, with approximately $7.3 billion in revenue[14] - Life Sciences represents 28.6% of 2025E total revenue, with approximately $7.3 billion in revenue[14] - Diagnostics represents >$6 billion of 2025E total revenue, with approximately $9.9 billion in revenue[14] - Bioprocessing consumables experienced high-single digit (HSD) growth, and equipment experienced mid-single digit (MSD) growth[12] Strategic Positioning & Growth Drivers - Approximately 80% of revenue is recurring, driven by razor/razor-blade models and service contracts[19] - Over 90% of global monoclonal antibody (mAb) production volume is supported by Cytiva[26] - Over 80% of 2025E bioprocessing revenue is from monoclonal antibodies (mAbs)[26]

Company Overview - Bel Fuse's annual sales are $657 million[6] - Adjusted EBITDA is $137 million, representing 20.9% of sales[6] - Original Equipment Manufacturers (OEM) account for 75% of Bel Fuse's customer base, while distributors make up 25%[10] - North America accounts for 65% of the company's geographic revenue, Asia 19%, and Europe 15%[10] Segment Performance - Power Solutions & Protection revenue was $224.4 million[12] - Connectivity Solutions revenue was $220.4 million[12] - Magnetic Solutions revenue was $210.6 million[12] - Aerospace/Defense TTM revenue was $163.5 million[12] Financial Transformation - Gross Margin has increased from 24.7% in 2021 to 38.7% in TTM Q3-25[14] - Historical Revenue increased from $535 million in 2023 to $657 million in TTM Q3-25[14] - Historical Adjusted EBITDA increased from $101.9 million in 2023 to $137.4 million in TTM Q3-25[18] Growth Drivers - Approximately 40% of Bel's sales support Aerospace & Defense applications[30] - Emerging end markets (Space & AI) have seen significant growth[31]